Production (Stage)
ZYUS Life Sciences Corporation
ZYUS.V
TSX
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -0.22% | 4.64% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -0.22% | 4.64% | |||
| Cost of Revenue | 2,296.33% | -3.54% | |||
| Gross Profit | -1,679.65% | 11.32% | |||
| SG&A Expenses | -19.80% | -32.87% | |||
| Depreciation & Amortization | 7.04% | -0.51% | |||
| Other Operating Expenses | 422.35% | -79.60% | |||
| Total Operating Expenses | 13.77% | -20.43% | |||
| Operating Income | -14.24% | 21.07% | |||
| Income Before Tax | -488.66% | 18.25% | |||
| Income Tax Expenses | -11,541.60% | -0.81% | |||
| Earnings from Continuing Operations | -440.57% | 18.31% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -440.57% | 18.31% | |||
| EBIT | -14.24% | 21.07% | |||
| EBITDA | -31.19% | 24.88% | |||
| EPS Basic | -424.62% | 19.76% | |||
| Normalized Basic EPS | -14.80% | 19.61% | |||
| EPS Diluted | -424.87% | 22.27% | |||
| Normalized Diluted EPS | -14.80% | 19.61% | |||
| Average Basic Shares Outstanding | 3.04% | 1.89% | |||
| Average Diluted Shares Outstanding | 3.04% | 1.89% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||